With the emerging use of real-world data (RWD) and/or synthetic data in clinical trials to support safety and efficacy claims, the European Commission is keenly awaiting the first set of results from half a dozen projects it is funding to harness the use of such data for regulatory decision-making and health technology assessment (HTA).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?